Today on World Movement Disorders Day, we recognize the impact of #Parkinsons & this year’s theme: “What Moves You?” Nearly 90,000 are diagnosed each year in the U.S., with <9M affected worldwide. We stand with patients, caregivers, & the community driving progress. #MoveDisorder

That’s a wrap on #MDSCongress 2025! Grateful for the chance to share additional Phase 1 results of our LRRK2 inhibitor NEU-411 and connect with so many working to advance care for people living with #Parkinsons.

We’re looking forward to the 2025 #MDSCongress, where we’ll share Phase 1 results of NEU-411 in healthy participants and showcase our NEULARK trial at our booth. Visit us to learn more about our work and the future of precision medicine in #Parkinsons.

We're proud of Dr. Nahab for presenting at the 2025 Grand Challenges in #Parkinsons Disease, hosted by the @VAInstitute. He discussed patient stratification in research & how our mission to bring precision medicine approaches to LRRK2-driven PD is bringing us closer to patients.

Traditions take many forms. For us, one of them is our annual SF Giants outing! Bringing the team together for another game was a great opportunity to connect outside of work & continue strengthening our relationships to foster a collaborative environment that drives success.

The summer's ending, but we're keeping the energy afloat as we took the team to celebrate our milestones to date. This year has been a rollercoaster, but the ride doesn’t end here. We look forward to continuing to create precision medicines to fight debilitating diseases.

Congrats to our recent executive promotions: Arash Rassoulpour as Chief Operating Officer & Steve Wood as Chief Scientific Officer! Their new roles will help drive our mission forward of advancing precision medicine for patients affected by debilitating neurological diseases.

This financing round further supports the progression of the NEULARK trial, which utilizes the first-ever companion diagnostic in PD to select people with LRRK2-driven disease & incorporates a unique digital biomarker to frequently monitor disease progression.

Read the details: https://t.co/EDpWMVUN6w We are pleased to announce the closing of our Series D financing round and the dosing of the first patient in our global Phase 2 NEULARK clinical trial of NEU-411 in people with early #Parkinsons.

It was another successful year at the annual #Move4PD San Jose Walk! This event brought the community together to honor those affected by #Parkinsons disease, raise awareness & support the critical work of @ParkinsonDotOrg. Thanks to all who showed up to make a difference.

Today is #WorldParkinsonsDay. We’re joining the global effort to raise awareness & end the stigma around Parkinson’s disease, which affects 10M people worldwide. At Neuron23, we’re committed to slowing disease progression & transforming treatment for better patient outcomes.

Neuron23 leadership attended #ADPD2025 in Vienna last week, joining experts to explore the latest in neurodegenerative disease research. We remain committed to driving innovation in #Parkinsons treatment with a more precise & potentially more effective approach.

April is #ParkinsonsAwarenessMonth, & we’re grateful to the @ParkinsonDotOrg visitors who shared how events like Moving Day impact the community. Their stories of resilience & advocacy inspire us. Join us in supporting them at Moving Day San Jose here: https://t.co/dPGbOHDreD

https://t.co/xNe7PvisJu

Our CMO Dr. Sam Jackson recently contributed to @ClinicalLeader1, discussing how diagnostic-based patient selection, digital solutions & partnerships are driving #precisionmedicine for Parkinson’s, including our NEULARK trial evaluating patients with LRRK2-driven PD. Read below.

We're proud to share that our CEO Nancy Stagliano was named one of the Most Influential Women in Bay Area Business by the @SFBusinessTimes. This honor reflects her exceptional leadership & commitment to innovation in #neurodegenerative & autoimmune diseases. Congrats, Nancy!

Today, a manuscript has been published in @PNASnews. This research outlines TYK2’s critical role in #neuroinflammation and explores the potential of TYK2 inhibition in #multiplesclerosis. Read more here: https://t.co/Ymlh0HUCf8

Neuron23 will attend the 2025 @adpdnet International Conference on Alzheimer’s & Parkinson’s Diseases to present data from the healthy volunteer trial of NEU-411, a LRRK2 inhibitor for #Parkinsons disease. For the poster presentation details, visit: https://t.co/EpmN22IXeq

#InternationalWomensDay is an opportunity to celebrate the incredible women of Neuron23 and beyond - scientists, leaders, mothers, daughters, and friends - who inspire, innovate, and shape the world. Here’s to breaking barriers and lifting each other up every day.

#MSAwarenessMonth is a time to amplify the fight against multiple sclerosis. MS occurs when the immune system attacks the central nervous system & we’re advancing research on TYK2 as a potential target for new therapies. Click below to find resources to support the MS community.